8-K: Liminatus Pharma Faces Nasdaq Delisting

Liminatus Pharma received a delisting notice from Nasdaq for failing to meet market value requirements, but has requested an appeal.

Summary

• Liminatus Pharma, Inc. received a notice from Nasdaq on May 20, 2026, stating it has not regained compliance with the Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS) requirements.
• The company was previously notified on November 25, 2025, that it failed to meet these requirements and was given 180 days, until May 18, 2026, to regain compliance.
• Trading of the company's common stock and warrants is scheduled for suspension at the opening of business on May 29, 2026, unless an appeal is requested.
• The company requested an appeal before the Nasdaq Hearings Panel on May 26, 2026, which will stay any delisting actions pending the hearing.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the confirmed failure to meet listing requirements and the impending delisting risk, despite the appeal process.

Positives

• The company has requested an appeal to the Nasdaq Hearings Panel, which will stay any delisting actions pending the hearing.
• The company has the opportunity to present its case to the Panel to potentially avoid delisting.

Negatives

• Liminatus Pharma has failed to regain compliance with Nasdaq's MVLS and MVPHS listing rules.
• The company's securities are subject to suspension from trading on May 29, 2026, if the appeal is not successful.
• Failure to regain compliance indicates significant market valuation challenges for the company.

Risks

• The primary risk is the delisting of the company's securities from The Nasdaq Global Market, which would significantly impact liquidity and investor confidence.
• There is no assurance that Nasdaq will accept the company's plan to regain compliance or that the company will ultimately regain compliance.
• A delisting could lead to a substantial decrease in the market price of the company's stock and warrants.
• The company may face difficulties in accessing capital markets if its securities are delisted.

Future Outlook

The future outlook is uncertain, pending the outcome of the Nasdaq Hearings Panel appeal. There is no guarantee that the company will regain compliance with Nasdaq's listing rules or that its securities will remain listed.

Management Comments

• The company has requested an appeal before the Panel, and this request will result in a stay of any suspension or delisting action pending the hearing.

Industry Context

StockSavvy.ai notes that Nasdaq delisting notices are a common occurrence for companies struggling with market capitalization, often signaling underlying business challenges or a lack of investor confidence in their growth prospects.

Stakeholder Impact

• Shareholders may experience a significant decrease in the value of their holdings and reduced liquidity.
• Creditors and other business partners may view the delisting as a sign of financial distress, potentially impacting business relationships.
• Employees may face uncertainty regarding job security and company stability.

Next Steps

• The company will await the decision from the Nasdaq Hearings Panel following the appeal.
• Trading suspension will occur on May 29, 2026, if the appeal is not successful or if the stay is lifted.
• A Form 25-NSE will be filed with the SEC to remove the company's securities from listing on Nasdaq if the delisting is finalized.

Key Dates

Recommendation

The confirmed failure to meet Nasdaq's listing requirements and the impending delisting pose significant risks to the company's liquidity and market standing. While an appeal is pending, the underlying issues leading to non-compliance suggest a deteriorating financial or market position, making it prudent for investors to consider selling.

Keywords

Liminatus Pharma, Nasdaq Delisting, Form 8-K, Listing Rules, MVLS, MVPHS, Securities Trading, Company Appeal